Safety of Live Attenuated MMR, Varicella, and Yellow Fever Vaccination in Patients with Inflammatory Bowel Disease Receiving Biologic and Targeted Synthetic Therapy: A Propensity-Score-Matched Analysis

Introduction: Live attenuated vaccines (LAVs) are generally avoided in patients with inflammatory bowel disease (IBD) receiving immunomodulatory therapy due to concerns about infection risk. However, real-world data evaluating their safety in this population remain limited. We aimed to assess advers...

詳細記述

書誌詳細

出版年:	Vaccines
主要な著者:	Niven Wang, Abdelrahman Yousef, Kevin Nguyen, Timothy Mok, Mahmoud Yousef, Ahmed Telbany, Abu Baker Sheikh, Christopher Chang, Swathi Paleti
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2026-05-01
主題:	inflammatory bowel disease live attenuated vaccines immunomodulatory therapy infliximab vedolizumab
オンライン･アクセス:	https://www.mdpi.com/2076-393X/14/6/474